Stock comparison
argenx SE
Genmab A/S
Scored across Buffett, Graham, Lynch and Greenblatt - plus a side-by-side metric table covering valuation, quality, growth and balance sheet.
ARGX
argenx SE
Market cap
$49.91B
Sector
Healthcare
GMAB
Genmab A/S
Market cap
$16.5B
Sector
Healthcare
Overall winner
argenx SE ARGX
Wins on the combined sum of fit scores across all four strategies. Per-strategy breakdown below.
Fit scores by strategy
| Strategy | ARGX | GMAB | Winner |
|---|---|---|---|
| Warren Buffett | 60C | 65C | GMAB |
| Benjamin Graham | 74D | 64C | ARGX |
| Philip Fisher | 80C | 48D | ARGX |
| Peter Lynch | 71B | 25F | ARGX |
| Joel Greenblatt | 57C | 76B | GMAB |
| Charlie Munger | 59D | 68C | GMAB |
| Terry Smith | 53D | 71C | GMAB |
Side-by-side metrics
| Metric | ARGX | GMAB |
|---|---|---|
| Market cap | $49.91B | $16.5B |
| P/E (TTM) | 44.1x | 6.2x |
| EV/EBIT | 44.4x | 12.0x |
| ROIC (TTM) | 11.74% | 43.78% |
| Gross margin | 89.0% | 93.88% |
| Net margin | 33.42% | 18.23% |
| Revenue CAGR 5y | 70.0% | -18.45% |
| EPS CAGR 5y | 42.58% | -23.48% |
| Debt / Equity | 0.0x | 0.1x |
| Dividend yield | 0.0% | 0.0% |
Where each one wins
The metrics with the biggest gap between the two - sorted so the most decisive edges read first.
ARGX leads on
- EPS CAGR 5y42.58%vs -23.48%+155%
- Revenue CAGR 5y70.0%vs -18.45%+126%
- Debt / Equity0.0xvs 0.1x+85%
- Market cap$49.91Bvs $16.5B+67%
GMAB leads on
- P/E (TTM)6.2xvs 44.1x+86%
- ROIC (TTM)43.78%vs 11.74%+73%
- EV/EBIT12.0xvs 44.4x+73%
- Gross margin93.88%vs 89.0%+5%
Related on invest-like
Key terms in this analysis
Educational tool. Fit scores are deterministic projections from public financials onto each investor's published criteria - not personal recommendations or advice.